MBX (MBX Biosciences) Buyback Yield %: -3.44 (As of Jun. 29, 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $54.01
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Buyback Yield %?

MBX Biosciences MBX +3.44% 12 Buyback Yield % is -3.44 as of Jun. 29, 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, MBX Biosciences ranks better than 64.42% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

MBX Biosciences's current buyback yield was -3.44%.

MBX Biosciences Buyback Yield % Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Buyback Yield % Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 -28.34 -13.26

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -13.26 -6.01

MBX vs SLS, TRVI, BHVN: Buyback Yield % Comparison

For the Biotechnology subindustry, MBX Biosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Buyback Yield % falls into.


MBX
12GF Score
MBX Biosciences Inc MBX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

MBX Biosciences's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 187.948) / 1417.02912
=-13.26%

MBX Biosciences's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 85.371) / 1419.9645
=-6.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -3.44 mean?
MBX Biosciences (MBX) has a Buyback Yield % of -3.44 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MBX Biosciences and its competitors. According to the industry distribution chart, MBX Biosciences ranks #264 out of 742 companies in the Biotechnology industry, placing it in the top 35.6%.
Is MBX Biosciences' Buyback Yield % too high?
MBX Biosciences' current Buyback Yield % is -3.44. Based on the distribution chart, MBX Biosciences ranks #264 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Buyback Yield % compare to SLS and TRVI?
According to the Biotechnology industry distribution chart, MBX Biosciences ranks #264 out of 742 companies for Buyback Yield %. This puts MBX Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current Buyback Yield % is -3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Buyback Yield % of -3.44. The current Buyback Yield % is -3.44. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Buyback Yield % is -3.44 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.01
Price